MSKCC Implementation of Active Surveillance for Thyroid Cancer
Memorial Sloan Kettering Cancer Center’s experience shows that selected patients with low-risk papillary thyroid cancer can safely defer surgery in favor of active surveillance.
I-131 for Thyroid Cancer Metastases
In this interview we discuss which distant metastases in thyroid cancer are appropriate targets for I-131 treatment, appropriate dosing, and more.
PI3K, HDAC Inhibition With CUDC-907 Shows Promise in Thyroid Cancer
Dual inhibition of PI3K signaling and histone deacetylase 2 (HDAC2) enzymes with CUDC-907 slowed thyroid tumor cell proliferation, tumor progression and metastasis, according to a preclinical study.
Metformin Delays Progression of Thyroid Tumor Metastases in Mice
Mitochondrial glycerophosphate dehydrogenase (mGPDH) is overexpressed in differentiated thyroid cancer (DTC) tissue, and metformin, which downregulates mGPDH, is associated with slowed growth in metastatic DTC tumors in mice.
Immunotherapy Patients Should Be Monitored for Destructive Thyroiditis
The risk of immunotherapy-related destructive thyroiditis requires close patient monitoring and can cause permanent hypothyroidism.
Long-Term Data Validate Low-Dose I-131 for Low-Risk Thyroid Cancer
Five years after treatment, low-dose postsurgical radioiodine (I-131) ablation for low-risk thyroid cancer offers outcomes equivalent to those seen following higher-dose ablation, according to a long-term follow-up analysis by French researchers.
Papillary Thyroid Microcarcinoma: Surveillance or Immediate Biopsy, Surgery?
As part of our coverage of the 2016 American Thyroid Association Annual Meeting we discuss active surveillance vs immediate lobectomy or thyroidectomy in papillary thyroid microcarcinoma.
MassARRAY Mutation-Detection Panel Improves Presurgical Thyroid Cancer Diagnosis
A MALDI-TOF mass spectrometry (MassARRAY) mutation-detection panel shows promise for improving the presurgical diagnosis of thyroid cancers with fine needle aspirations, according to a pilot study.
Clinical Management of Medullary Thyroid Carcinoma
In this interview on medullary thyroid carcinoma we discuss treatment strategies, prognostic biomarkers, surveillance following treatment, and more.
Study Validates ATA Ultrasonographic Thyroid Nodule Risk Assessment
High-risk ultrasound findings strongly indicate that thyroid nodules are malignant, even when nodules are cytologically indeterminate following find needle aspiration.
Weekly Paclitaxel Safe, Well-Tolerated in Anaplastic Thyroid Carcinoma
A Japanese study found that weekly paclitaxel was safe and well-tolerated among patients with anaplastic thyroid carcinoma, a notoriously aggressive malignancy.
PD-L1 a Potential Target in Thyroid Cancer?
Immune checkpoint inhibitor therapy is looking increasingly plausible as a potential investigative strategy for treating thyroid cancers.
TERT/BRAF Mutations a Deadly Combo for Thyroid Cancer Patients
The coexistence of mutations in telomerase reverse transcriptase (TERT) and BRAF genes dramatically increases the risk of thyroid cancer aggressiveness, tumor recurrence and thyroid cancer-specific deaths.
Markers in Medullary Thyroid Cancer May Signal Metastasis, Vandetanib Response
Researchers in Germany appear to have identified a gene-expression signature associated with metastasis in sporadic medullary thyroid cancer and prognostic molecular tumor markers of medullary thyroid cancer response to vandetanib therapy.
Remnant Tumor Ablation Should Be Selective, Not Routine
New ATA Guidelines offer clear and welcome guidance against routine post-thyroidectomy remnant tumor ablation with radioactive iodine, agreed experts at the 85th Annual Meeting of the ATA.
Superior Survival Seen With Aggressive Therapy in Anaplastic Thyroid Cancer
For patients who can tolerate aggressive multimodal therapy for anaplastic thyroid carcinoma, survival rates can exceed historical outcomes, according to a retrospective study of patients treated at the Mayo Clinic.
Role of Fukushima Radiation Unclear in Pediatric Thyroid Cancers?
It is too soon to determine the influence of radiation exposure on thyroid cancer risk among children and adolescents exposed to the 2011 Fukushima Daiichi nuclear power plant disaster in Japan, according to the lead author of findings presented at the 85th Annual Meeting of the ATA.
ATA Updates Guidelines for Differentiated Thyroid Cancers
Release of newly revised, evidence-based clinical management guidelines for thyroid nodules and differentiated thyroid cancers were announced at the 85th Annual Meeting of the ATA.
Autophagy Implicated in Vemurafenib Resistance in BRAF-Mutant Thyroid Cancer
Preclinical findings suggest that autophagy inhibition might prove useful in overcoming BRAF-mutant thyroid cancers resistant to vemurafenib.
FAM83F Protein Implicated in Papillary Thyroid Cancer and Drug Resistance
The FAM83F protein contributes to papillary thyroid cancer cell viability and doxorubicin resistance, according to a study presented at the 85th Annual Meeting of the ATA.
2 Clarke Drive Cranbury, NJ 08512